CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Ramanan, Vyas ^a   Shlomai, Amir ^b,i   Cox, David B T ^a,f   Schwartz, Robert E ^a,c,d   Michailidis, Eleftherios ^b   Bhatta, Ankit ^b   Scott, David A ^f,h   Zhang, Feng ^a,f,h   Rice, Charles M ^b   Bhatia, Sangeeta N ^a,c,e,f,g  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e Department of Electrical Engineering and Computer Science   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^g HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^h MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

ⁱ TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CIRCULAR DNA; CRISPR ASSOCIATED PROTEIN; GUIDE RNA; VIRUS DNA;

ANIMAL; CELL CULTURE; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; CRISPR CAS SYSTEM; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE TARGETING; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; METABOLISM; MOUSE; TUMOR CELL LINE; VIROLOGY; VIRUS REPLICATION;

ANIMALS; CELL LINE, TUMOR; CELLS, CULTURED; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-ASSOCIATED PROTEINS; CRISPR-CAS SYSTEMS; DISEASE MODELS, ANIMAL; DNA, CIRCULAR; DNA, VIRAL; GENE EXPRESSION REGULATION, VIRAL; GENE TARGETING; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MICE; RNA, GUIDE; VIRUS REPLICATION;

EID: 84934877005     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep10833     Document Type: Article

References (30)

1. Dienstag, J. L. Hepatitis B Virus Infection. New England Journal of Medicine 359, 1486-1500, doi:doi:10.1056/NEJMra0801644 (2008).
2. Ganem, D. & Varmus, H. E. The molecular biology of the hepatitis B viruses. Annu Rev Biochem 56, 651-693 (1987).
3. Shlomai, A. & Rice, C. M. Getting Rid of a Persistent Troublemaker to Cure Hepatitis. Science 343, 1212-1213, doi:10.1126/science.1252186 (2014).
4. Lucifora, J. et al. Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA. Science, doi:10.1126/science.1243462 (2014).
5. Bloom, K., Ely, A., Mussolino, C., Cathomen, T. & Arbuthnot, P. Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector Nucleases. Mol Ther 21, 1889-1897, doi:10.1038/mt.2013.170 (2013).
6. Chen, J. et al. An Efficient Antiviral Strategy for Targeting Hepatitis B Virus Genome Using Transcription Activator-Like Effector Nucleases. Mol Ther 22, 303-311, doi:10.1038/mt.2013.212 (2014).
7. Weber, N. D. et al. AAV-Mediated Delivery of Zinc Finger Nucleases Targeting Hepatitis B Virus Inhibits Active Replication. PLoS ONE 9, e97579, doi:10.1371/journal.pone.0097579 (2014).
8. Cong, L. et al. Multiplex Genome Engineering Using CRISPR/Cas Systems. Science 339, 819-823, doi:10.1126/science.1231143 (2013).
9. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823-826, doi:10.1126/science.1232033 (2013).
10. Hu, W. et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proceedings of the National Academy of Sciences, doi:10.1073/pnas.1405186111 (2014).
11. Lewis, D. L. & Wolff, J. A. Delivery of siRNA and siRNA expression constructs to adult mammals by hydrodynamic intravascular injection. Methods Enzymol 392, 336-350 (2005).
12. Shalem, O. et al. Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science 343, 84-87, doi:10.1126/science.1247005 (2014).
13. Sells, M. A., Chen, M.-L. & Acs, G. Production of Hepatitis B Virus Particles in Hep G2 Cells Transfected with Cloned Hepatitis B Virus DNA. PNAS 84, 1005-1009, doi:10.1073/pnas.84.4.1005 (1987).
14. Yan, H. et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 1, doi:10.7554/eLife.00049 (2012).
15. Qi, L. S. et al. Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression. Cell 152, 1173-1183, doi:10.1016/j.cell.2013.02.022 (2013).
16. Lin, Y. et al. CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences. Nucleic Acids Research 42, 7473-7485, doi:10.1093/nar/gku402 (2014).
17. Marraffini, L. A. & Sontheimer, E. J. CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea. Nat Rev Genet 11, 181-190 (2010).
18. Nagaya, T. et al. The mode of hepatitis B virus DNA integration in chromosomes of human hepatocellular carcinoma. Genes Dev 1, 773-782 (1987).
19. Lin, S.-R. et al. The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates in vivo. Mol Ther Nucleic Acids 3, e186, doi:10.1038/mtna.2014.38 (2014).
20. Seeger, C. & Sohn, J. A. Targeting Hepatitis B Virus With CRISPR/Cas9. Molecular Therapy. Nucleic Acids 3, e216, doi:10.1038/mtna.2014.68 (2014).
21. Kennedy, E. M. et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology 476, 196-205, doi:http://dx.doi.org/10.1016/j.virol.2014.12.001 (2015).
22. Zhen, S. et al. Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated Cas9 system to disrupt the hepatitis B virus. Gene Ther, doi:10.1038/gt.2015.2 (2015).
23. Cox, D. B. T., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat Med 21, 121-131, doi:10.1038/nm.3793 (2015).
24. Cohen, D., Adamovich, Y., Reuven, N. & Shaul, Y. Hepatitis B virus activates deoxynucleotide synthesis in nondividing hepatocytes by targeting the R2 gene. Hepatology 51, 1538-1546, doi:10.1002/hep.23519 (2010).
25. Doitsh, G. & Shaul, Y. Enhancer I Predominance in Hepatitis B Virus Gene Expression. Molecular and Cellular Biology 24, 1799-1808, doi:10.1128/mcb.24.4.1799-1808.2004 (2004).
26. Glebe, D. et al. Pre-S1 Antigen-Dependent Infection of Tupaia Hepatocyte Cultures with Human Hepatitis B Virus. Journal of Virology 77, 9511-9521, doi:10.1128/jvi.77.17.9511-9521.2003 (2003).
27. Cai, D. et al. in Antiviral Methods and Protocols Vol. 1030 Methods in Molecular Biology (ed Edwin Yunhao Gong) Ch. 13, 151-161 (Humana Press, 2013).
28. Sapranauskas, R. et al. The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic Acids Research 39, 9275-9282, doi:10.1093/nar/gkr606 (2011).
29. Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotech 31, 827-832, doi:10.1038/nbt.2647 (2013).
30. Ran, F.A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature, the doi is 10.1038/nature14299 (2015).